drugset

drugset / Trial / NCT01193179

A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes

NCT01193179 ↗

Phase 3 Completed 450 enrolled Kyowa Kirin, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety of OPC-262 administered orally in combination with another oral antihyperglycemic agent

Timeline

Start: 2010-07
Primary completion: 2012-04
Completion: 2012-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OPC-262	Unknown	—	Oral

Indications